The treatment strategy involved three i.c. injections of AAVF vectors over 3 days, within a time frame that would not trigger anti-AAVF immunogenicity73 but still guaranteed sufficient Tnfsf9 expression at the tumor site. The gene discussed is TNFSF9; the disease is neoplasm.